EDUARDO, Mariana Bustamante, Vlad POPOVICI, Sara IMBODEN, Stefan AEBI, Nadja BALLABIO, Hans Jorg ALTERMATT, Andreas GUNTHERT a Rolf JAGGI. Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases. BMC Cancer. London: BioMed Central, 2019, roč. 19, June, s. 1-14. ISSN 1471-2407. Dostupné z: https://dx.doi.org/10.1186/s12885-019-5752-8.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases
Autoři EDUARDO, Mariana Bustamante (756 Švýcarsko), Vlad POPOVICI (642 Rumunsko, garant, domácí), Sara IMBODEN (756 Švýcarsko), Stefan AEBI (756 Švýcarsko), Nadja BALLABIO (756 Švýcarsko), Hans Jorg ALTERMATT (756 Švýcarsko), Andreas GUNTHERT (756 Švýcarsko) a Rolf JAGGI (756 Švýcarsko).
Vydání BMC Cancer, London, BioMed Central, 2019, 1471-2407.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW Full Text
Impakt faktor Impact factor: 3.150
Kód RIV RIV/00216224:14310/19:00110435
Organizační jednotka Přírodovědecká fakulta
Doi http://dx.doi.org/10.1186/s12885-019-5752-8
UT WoS 000470702000003
Klíčová slova anglicky Breast cancer; Molecular risk scores; Local recurrence; Brain metastasis; PAM50 subtypes; Gene expression measurement; Immunohistochemistry; RNA isolation and processing; Hierarchical clustering
Štítky rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Marie Šípková, DiS., učo 437722. Změněno: 24. 3. 2020 11:29.
Anotace
BackgroundBreast cancer is a leading cause of cancer-related death in women worldwide. Despite extensive studies in all areas of basic, clinical and applied research, accurate prognosis remains elusive, thus leading to overtreatment of many patients. Diagnosis could be improved by introducing multigene molecular scores in standard clinical practice. Several tests that work with formalin-fixed tissue have become routine. Molecular scores usually include several genes representing processes, response to oestrogens, progestogens and human epidermal growth factor receptor 2 (Her2), respectively, which are combined additively in single values. These multi-gene scores have the advantage of being more robust and reproducible than single-gene scores. Their utility may be further enhanced by combining them with classical diagnostic parameters. Here, we present an exploratory study comparing the RISK and research versions of Oncotype DX recurrence score (RS), Prosigna Risk of Recurrence (ROR) and EndoPredict (EP) with respect to their prognostic potential for ipsilateral recurrence and/or distant relapse in brain, and we compared the scores to the intrinsic subtypes based on PAM50.MethodsRNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tissue cores of primary tumours, local recurrences and brain metastases. Gene expression was measured on a NanoString nCounter Analysis System. Intrinsic subtypes and molecular scores were computed according to published literature and RISK, RS, ROR and EP were compared against each other and to the intrinsic subtypes Luminal A (lumA), Luminal B (lumB), Her2-enriched (Her2), Basal-like (basal), and Normal-like (normal) of PAM50. Local recurrences and brain metastases were compared to their corresponding primary tumours.ResultsAll four molecular scores were highly correlated. Highest correlations were observed among genes related to proliferation while lower correlations were found among oestrogen-related genes. The scores were significantly higher in primary tumours progressing to brain metastases as compared to recurrence-free primary tumours and primary tumours that relapsed as local recurrences.ConclusionsRISK and ROR-P are prognostic for primary tumours metastasizing to the brain. All four scores, RISK, RS, EP and ROR-P failed to discriminate between primary tumours that remained recurrence-free and primary tumours relapsing as local recurrences.
Návaznosti
EF16_013/0001761, projekt VaVNázev: RECETOX RI
LM2015051, projekt VaVNázev: Centrum pro výzkum toxických látek v prostředí (Akronym: RECETOX RI)
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Výzkumná infrastruktura RECETOX
VytisknoutZobrazeno: 2. 9. 2024 00:15